𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetic–pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model

✍ Scribed by Takayuki Katsube; Yoshitaka Yano; Yoshinori Yamano; Tadashi Munekage; Naomi Kuroda; Mikihisa Takano


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
157 KB
Volume
97
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


A pharmacokinetic (PK)/pharmacodynamic (PD) modeling strategy to explain the data from an in vitro dynamic model is proposed. Two carbapenem antibiotics, doripenem and meropenem, and three Pseudomonas aeruginosa strains were used as example drugs and strains. The PD model we originally developed to explain the in vitro time-kill data was modified by incorporating bactericidal activities and simulated in vivo PK profiles of the drugs. By employing only one parameter regarding the bactericidal activity from the data at a certain dosage regimen, the bacterial profiles at various dosage regimens could be well simulated for both antibiotics by the PK/PD model. Moreover, simulated bacterial counts for various dosage regimens correlated with time above minimum inhibitory concentration derived from free drug concentrations (fT > MIC) for doripenem. The predicted fT > MIC values to achieve PK/PD endpoints for three strains (static effect: 25.0%, 23.9%, and 39.8%, 2-log killing effect: 28.1%, 29.5%, and 49.6%, 90% maximum killing effect: 36.5%, 46.8%, and 80.7%) were similar to those estimated from free drug concentrations in animal infection models. The proposed in vitro PK/PD model would be useful for simulating bactericidal kinetics in the dynamic model and predicting the human therapeutic target for PK/PD indices estimated from animal infection models.


📜 SIMILAR VOLUMES


Pharmacokinetic–pharmacodynamic modeling
✍ Takayuki Katsube; Yoshinori Yamano; Yoshitaka Yano 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB

A pharmacokinetic (PK)/pharmacodynamic (PD) modeling strategy to simulate in vivo bactericidal effects for three carbapenem antibiotics, doripenem (DRPM), meropenem (MEPM)/cilastatin (CS), and imipenem (IPM)/CS, against a Pseudomonas aeruginosa (P. aeruginosa) strain is proposed. The PD model we hav

Pharmacokinetic/pharmacodynamic modeling
✍ Katsube, Takayuki (author);Yano, Yoshitaka (author);Wajima, Toshihiro (author);Y 📂 Article 📅 2010 🏛 John Wiley and Sons Inc. 🌐 English ⚖ 170 KB

The aim of this study was to obtain information on effective dosage regimens of doripenem by a modeling and simulation approach based on pharmacokinetic (PK)/pharmacodynamic (PD) theory. The PK/PD model we have already developed was modified to explain in vitro bactericidal kinetics of doripenem for

Application of pharmacokinetic–pharmacod
✍ Evelyn D. Lobo; David M. Soda; Joseph P. Balthasar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

We have shown that intravenous (i.v.) administration of anti-methotrexate (MTX) antibodies (AMAb) reduces the systemic exposure of intraperitoneal (i.p.) MTX therapy, and we have proposed that AMAb effects on MTX systemic exposure would allow a reduction in MTX-induced systemic toxicity (i.e., produ

Retracted: Convulsant activity and pharm
✍ Bikash Roy; Anirbandeep Bose; Uttam Bhaumik; Ayan Das; Nilendra Chatterjee; Anim 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB

A pharmacokinetic-pharmacodynamic (PK-PD) modeling approach was used to investigate the epileptogenic activity of gemifloxacin as a representative antibiotic with concentration-dependent antimicrobial activity. Rats received an intravenous infusion of gemifloxacin at a rate of 4 mg kg of body weight